Latest Breaking News On - Serious side - Page 8 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A July 19, 2021 GMT SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Jul 19, 2021 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the final analysis of the Phase IIIb STASEY study, which confirm the favorable safety profile of Hemlibra ® (emicizumab-kxwh), consistent with the Phase III HAVEN clinical program. In the analysis, no new safety signals were identified with longer-term Hemlibra treatment in adults and adolescents with hemophilia A with inhibitors to factor VIII, the clotting protein that is missing or defective in people with hemophilia A. The data were presented at the virtual International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, July 17-21.

United statesSouth san franciscoLevi garrawayKarl mahlerLoren kalmGina truslowAdam pryorChugai pharmaceutical co ltdInternational society on thrombosisRoche groupGlobal product developmentInternational societyGlobal productPrescribing informationMedication guideSerious side